Template:Griseofulvin: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Griseofulvin|{{fontcolor|#6C7B8B|Griseofulvin}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Griseofulvin|{{fontcolor|#6C7B8B|Griseofulvin}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Grifulvin V<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Grifulvin V<sup>®</sup>,GRIS-PEG<sup>®</sup>  Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin description|Description]]
Line 19: Line 19:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin drug interactions|Drug Interactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Griseofulvin dosage and administration|Dosage and Administration]]

Latest revision as of 23:23, 5 January 2014